HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Online-Only Appendix All Versions of this Article: dc06-2532v1 30/11/2767    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davis, S. N. Articles by Brodows, R. G. Search for Related Content PubMed PubMed Citation Articles by Davis, S. N. Articles by Brodows, R. G. Social Bookmarking                What's this?

Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabetes Agents

¹ Endocrinology and Metabolism, Vanderbilt University, Nashville, Tennessee
² Eli Lilly, Indianapolis, Indiana
³ Amylin Pharmaceuticals, San Diego, California

Address correspondence and reprint requests to Dr. Stephen N. Davis, Endocrinology and Metabolism, Vanderbilt University, 715 PRB, 2220 Pierce Ave., Nashville, TN 37232-6303. E-mail: steve.davis{at}vanderbilt.edu

OBJECTIVE— This 16-week study explored the safety of substituting exenatide for insulin in patients with type 2 diabetes using insulin in combination with oral antidiabetes agents.

RESEARCH DESIGN AND METHODS— Successful maintenance of glycemic control was predefined as an A1C increase of <0.5%. A total of 49 patients (aged 53 ± 8 years, with BMI 34 ± 4 kg/m², A1C 8.1 ± 1.1%, and duration of diabetes 11 ± 7 years) were randomized to either substitute exenatide for insulin or remain on their current insulin regimen. Patients who either completed 8 weeks of study or discontinued because of loss of glycemic control were included in primary efficacy analysis.

RESULTS— A total of 62% (18 of 29) of the exenatide-treated patients maintained glycemic control compared with 81% (13 of 16) of the insulin-treated patients. Of the 11 exenatide-treated patients who did not maintain control, 5 discontinued before week 16 because of loss of glucose control. The overall safety profile was generally consistent with previous exenatide trials. The mean overall hypoglycemia rates were 1.72 and 0.97 events/patient-year for the exenatide and insulin reference groups, respectively.

CONCLUSIONS— This pilot study suggests that it is feasible to sustain glycemic control when substituting exenatide for insulin. Although it is not possible to characterize clear predictors of outcome given the size and exploratory nature of the study, the data suggest that patients with longer disease duration, who are taking higher doses of insulin and have less endogenous β-cell function, may experience deterioration in glucose control if exenatide is substituted for insulin therapy.

Abbreviations: SMBG, self-monitored blood glucose

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. F Van Gaal, S. W Gutkin, and M. A Nauck Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur. J. Endocrinol., June 1, 2008; 158(6): 773 - 784. [Abstract] [Full Text] [PDF]

				S. E. Inzucchi and D. K. McGuire New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond Circulation, January 29, 2008; 117(4): 574 - 584. [Abstract] [Full Text] [PDF]

				M. J. Fowler Diabetes Treatment, Part 3: Insulin and Incretins Clin. Diabetes, January 1, 2008; 26(1): 35 - 39. [Full Text] [PDF]

				J. Rosenstock and V. Fonseca Missing the Point: Substituting Exenatide for Nonoptimized Insulin: Going from bad to worse! Diabetes Care, November 1, 2007; 30(11): 2972 - 2973. [Full Text] [PDF]